M. Edward
M. Edward Medof, Pepper Pike, OH US
Patent application number | Description | Published |
---|---|---|
20100063146 | METHOD FOR TREATING DISORDERS RELATED TO COMPLEMENT ACTIVATION - A method for treating or preventing a complement activated T-cell mediated disorder in a subject includes administering a therapeutically effective amount of a pharmaceutical composition to the subject. The pharmaceutical composition includes at least one amidine compound or pharmaceutically acceptable salt. | 03-11-2010 |
20120219566 | COMPOSITIONS AND METHODS OF TREATING T CELL MEDIATED DISORDER - A method of generating a CD4 | 08-30-2012 |
20120226020 | HYBRID AND CHIMERIC POLYPEPTIDES THAT REGULATE ACTIVATION OF COMPLEMENT - A hybrid complement-regulating protein comprises a first functional unit of a first complement regulatory protein having complement regulating properties, a first spacer sequence of at least about 200 amino acids encoding a polypeptide that does not exhibit complement regulating properties and at least a second functional unit attached to the spacer sequence. The second functional unit may be a polypeptide providing a functional unit of a second complement regulatory protein, a polypeptide derived from an immunoglobulin, or a polypeptide that enhances binding of the protein to an animal cell. The hybrid protein may also contain a second spacer sequence and a third functional unit of a complement regulatory protein, a polypeptide derived from an immunoglobulin, and a polypeptide that enhances binding of the protein to an animal cell. The optional third functional unit may be the same or different from the first or second functional units. | 09-06-2012 |
20120315279 | COMPOSITIONS AND METHOD OF MODULATING GROWTH FACTOR FUNCTION - A method of modulating growth factor responses of cells expressing C3a receptor (C3aR) and C5a receptor (C5aR) and at least one growth factor receptor includes administering to the cells at least one agent that modulates C3aR and/or C5aR signaling of the cells. | 12-13-2012 |
M. Edward Medof, Pepperpike, OH US
Patent application number | Description | Published |
---|---|---|
20110135656 | METHOD OF TREATING CANCER - A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell. | 06-09-2011 |
20110182910 | METHOD OF TREATING T CELL MEDIATED DISORDERS - A method of treating a T-cell mediated disorders in a tissue includes administering to the tissue of the subject a therapeutically effective amount of a complement antagonist that substantially reduces T-cell differentiation or t-cell inflammatory cytokine generation. | 07-28-2011 |
M. Edward Medof, Cleveland, OH US
Patent application number | Description | Published |
---|---|---|
20150299300 | METHOD OF TREATING CANCER - A method for inducing apoptosis of a neoplastic cell expressing C3aR or C5aR includes administering at least one complement antagonist to the cell so that the at least one complement antagonist substantially reduces or inhibits the activity of protein kinase B in the neoplastic cell. | 10-22-2015 |
M. Edward Pierson, Jr., Wilmington, DE US
Patent application number | Description | Published |
---|---|---|
20090318415 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 - Compounds the following formula: | 12-24-2009 |
20110160184 | Dibenzothiazepine Derivatives and Use Thereof - Compounds the following formula: wherein Z is as described in the specification, pharmaceutically acceptable salts thereof, compositions comprising the same, and methods of treating bipolar disorder, an anxiety disorder, a mood disorder or schizophrenia or other psychotic disorder with said compounds. | 06-30-2011 |
20120202991 | DIBENZOTHIAZEPINE DERIVATIVES AND USES THEREOF - 424 - Compounds the following formula: | 08-09-2012 |